Attorney Docket No. 27053/2082 Date of Deposit: December 16, 2003 Express Mail No.: EL928104362US

## **Claims**

1. A compound of formula (I), or a pharmaceutically acceptable salt or a stereoisomer thereof:

Wherein,  $R_1$  and  $R_2$  may be the same or different and independently be  $C_{1-6}$  alkyl.

2. The compound according to claim 1, wherein said compound is 5-[[2-ethoxy-5-(cis-2,6-dimethypiperazin-4-ylsulphonyl)phenyl]]-1-methyl-3-n-propyl-7,6-dihydro-1H-pyrazolo[4,3-d]pyrimidin-7-one, and said compound has the structure of formula (I') as follows:

Attorney Docket No. 27053/2082 Date of Deposit: December 16, 2003 Express Mail No.: EL928104362US

3. A method for preparing the compound of formula (I'), comprising the following steps:

a. reacting 2-ethoxy benzoic acid, as raw materials, with chlorosulfonic acid in the presence of sulfoxide dichloride, obtaining 5-chlorosulphonyl-2-ethoxy benzoic acid (compound II);

b. reacting the compound II with cis-2,6-dimethyl piperazine, obtaining 2-ethoxy-5-(cis-2, 6-dimethyl piperazin-4-ylsulphonyl) benzoic acid (compound III);

c. nucleophilicacyl substitution of the compound III, obtaining 2-ethoxy-5-(cis-2,6- dimethylpiperazin-4-ylsulphonyl)benzoylchloride(IV);

Attorney Docket No. 27053/2082 Date of Deposit: December 16, 2003 Express Mail No.: EL928104362US

d. reacting the compound (IV) with the compound (V) in the presence of 4-dimethylaminopyridine and triethylamine, obtaining 4-[2-ethoxy-5-(cis-2,6-dimethylpiperazin-4-ylsulphonyl)benzamido]-1-methyl-3-n-propylpyrazole-5-carboxamide (compound VI);

e. cyclization of the compound VI in the present of potassium t-butoxide, obtaining 5-[[2-ethoxy-5-(cis-2,6-dimethylpiperazin-4-ylsulphonyl)phenyl]]-1-methyl- 3-n-propyl-7,6-dihydro-1H-pyrazolo[4,3-d] pyrimidin-7-one (I').

Attorney Docket No. 27053/2082 Date of Deposit: December 16, 2003

Express Mail No.: EL928104362US

4. A compound of formula (VI), which is 4-[2-ethoxy-5-(cis-2,6-dimethylpiperazin-4-ylsulphonyl)benzamido]-1-methyl-3-n-propyl-pyrazole-5-carboxamide, having the structure as follows:

- 5. A pharmaceutical composition for treating impotence, comprising a therapeutically effective amount of a compound of formula (I), its pharmaceutically acceptable salts or stereoisomers, as an active component, and a pharmaceutical acceptable carrier.
  - 6. The pharmaceutical composition according to claim 5, wherein the compound

Attorney Docket No. 27053/2082 Date of Deposit: December 16, 2003

Express Mail No.: EL928104362US

of formula (I) is 5-[[2-ethoxy-5-(cis-2,6-dimethylpiperazin-4-ylsulphonyl)phenyl]] -1-methyl-3-n-propyl-7,6-dihydro-1H-pyrazolo[4,3-d]pyrimidin-7-one.

- 7. A method of treating impotence diseases in a subject comprising administering to the subject a composition comprising a compound of formula (I).
- 8. The method of claim 7, wherein the compound of formula (I) is 5-[[2-ethoxy-5-(cis-2,6-dimethylpiperazin-4-ylsulphonyl)phenyl]]-1-methyl-3-n-propyl-7,6-dihydro-1H-pyrazolo[4,3-d]pyrimidin-7-one.